Jane Mounteney - Academia.edu (original) (raw)

Papers by Jane Mounteney

Journal of Geography, Politics and Society, May 27, 2022

(1), João Matias (2), Linda Montanari (2), Katerina Skarupova (2), Marica Ferri (2), Isabelle Gir... more (1), João Matias (2), Linda Montanari (2), Katerina Skarupova (2), Marica Ferri (2), Isabelle Giraudon (2), Jane Mounteney (2), Sandrine Sleiman (2), Katarzyna Natoniewska (2), Bruno Guarita (2), Liesbeth Vandam (2), Tim Surmont (2), Paul Griffiths (2)

Rus & avhengighet, Feb 7, 2002

desember 1980-«Smack in the Capital» er overskriften i utelivsbladet Time Out. Dette er den først... more desember 1980-«Smack in the Capital» er overskriften i utelivsbladet Time Out. Dette er den første kjente referansen til den nye trenden blant unge londonere; heroinrøyking, kjent som chasing the dragon. Tre år seinere nevner Community Drug Projects årlige rapport en økt forekomst av heroin på Londons gater og i en yngre klientgruppe. Det tar tid før de tradisjonelle tiltakene for rusmiddelbehandling blir klar over de nye brukerne, vant som de er til å arbeide med eldre injiserende heroinbrukere. I 1984 begynner «heroin-epidemi»overskrifter å dukke opp i rikspressen. De fokuserer på problemer i Sør-London og i kommunale boligområder i Wirral. I 1985, fem år etter at trenden ble plukket opp av ungdomsmediene, lanserer den britiske regjeringen den sterkt kritiserte «Heroin Screws You Up»-kampanjen. Enda seinere, i 1986-87 utgis sosiologiske og etnografiske studier som beskriver den nye heroin-trenden. Hvorfor var vi så trege? Hvorfor tok det så lang tid fra et nytt rusmiddel ble identifisert eller en oppdaget en ny måte å innta et eksisterende rusmiddel, til offentligheten fikk tilgang på informasjonen?

European Addiction Research

Introduction: Wastewater-based epidemiology (WBE) has emerged as a timely, non-invasive, and cost... more Introduction: Wastewater-based epidemiology (WBE) has emerged as a timely, non-invasive, and cost-effective indicator of illicit drug consumption. It is increasingly used by international organizations as a proxy measure for estimates of drug prevalence and related trends. Nevertheless, the literature exploring the limitations of WBE remains limited. This paper aims to shed further light on important shortcomings of WBE with recommendations on moving forward. Method: Utilizing case study and statistical analysis, the paper critically reviews methodological challenges associated with WBE results related to (i) levels, (ii) trends, and (iii) between-city comparisons of drug use. Data from raw influent wastewater samples from wastewater plants in the cities of Oslo, Bergen and Stavanger/Sandnes were analysed for amphetamine, methamphetamine, MDMA, and cocaine (benzoylecgonine) over a 3-year period. Normalized population loads were calculated and variation in daily loads analysed with p...

This monograph describes methods, instruments and indicators designed to enhance the evaluation o... more This monograph describes methods, instruments and indicators designed to enhance the evaluation of treatment programmes for drug users in the EU. Through a dozen expert papers and recommendations, the publication explores the theory of drug treatment evaluation and how the principles of such evaluation can be applied in practice and made relevant to practitioners. In particular, the monograph demonstrates how evaluation can help policy-makers take informed and appropriate decisions on treatment and help professionals boost the quality, relevance and cost-effectiveness of treatment services.

Clinical Pharmacology & Therapeutics, 2016

The information given is free, as are most calls (though some operators, phone boxes or hotels ma... more The information given is free, as are most calls (though some operators, phone boxes or hotels may charge you). More information on the European Union is available on the internet (http://europa.eu).

Substance Use & Misuse, 2000

Drug Information Systems (DIS) are called upon to provide an early warning of emerging trends in ... more Drug Information Systems (DIS) are called upon to provide an early warning of emerging trends in drug use. However, little theoretical attention is directed toward exploring conceptual issues in this area. In this paper a typology of existing DIS is oflered. Among the features that distinguish DIS are their structure (human network or organizational systems) and the range of information sources used. Indicators of drug use can be placed on a continuum of sensitivity ranging from leading edge indicators to lagged indicators. Sensitivity implies volatility as sensitive indicators also react to fluctuations that do no( become trends. DIS conventionally are largely reliant upon lagged indicators. What is required are DIS that combine a critical information processing function with the ongoing systematic collection of data from a range of data sources.

Adicciones, 2012

How to cite Complete issue More information about this article Journal's homepage in redalyc.org ... more How to cite Complete issue More information about this article Journal's homepage in redalyc.org Scientific Information System Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Non-profit academic project, developed under the open access initiative EDITORIAL Drawing on an analysis of data from over 30 cohort studies, it can be estimated that between 10.000 and 20.000 opioid users die each year in Europe. Typically, annual mortality rates are between 10-20/1000, representing an excess mortality 10 to 20 times greater than expected. Most deaths occur among males in their mid-thirties. Four broad categories of cause of death can be identified: overdoses, diseases, suicide and trauma. While the long term trend in HIV related mortality among drug users is downwards, other causes of mortality have shown little sign of decreasing in recent years. Of particular concern are overdoses which account for 6300 to 8400 deaths reported annually. The fact that deaths have not decreased is surprising given the scaling up of treatment and other services. Opioid substitution treatment in particular is known to be protective and the numbers of those in substitution treatment in Europe has increased dramatically. A number of interrelated factors may help explain this intractable problem. These include: the possibility of an aging cohort becoming more vulnerable; the use of alcohol and other drugs; high levels of ill-health, risk behaviour, and co-morbidity; and social exclusion and marginalisation. Reducing overall morbidity among heroin users remains a key issue for Europe's public health services. More efforts are required to better understand and target both the direct and indirect factors associated with mortality among problem drugs users, if this major health cost associated with drug consumption is to be reduced.

The European Monitoring Centre for Drugs and Drug Addiction(EMCDDA) is the designated hub for dru... more The European Monitoring Centre for Drugs and Drug Addiction(EMCDDA) is the designated hub for drug-related information in the European Union.The organization’s role is to provide the European Union (EU) and its Member States with a factual overview of European drug problems and a common information framework to support the drugs debate. In order to achieve its mission, the EMCDDA coordinates and relies on a network of 30 national monitoring centres, the Reitox National Focal Points. The Centre publishes on a wide range of drug-related topics, across epidemiology, interventions, laws and policies. Every November, the EMCDDA publishes its Annual Report, providing a yearly update on the European drug situation, translated into 23 EU languages. In line with its founding regulation, the EMCDDA has a role acting as an interface between theworlds of science and policy.While not a research centre in the formal sense, the results the Centre generates serve as catalysts for new research questions and help to identify priorities. Current challenges facing the agency include continuing to increase scientific standardswhile maintaining a strong institutional role, as well as supporting European efforts to identify, share and codify best practice in the drugs field.

Addiction Research Methods

Drugs: Education, Prevention, and Policy, 2013

May 2013 saw the publication of the first European Drug Report (EDR), the European Monitoring Cen... more May 2013 saw the publication of the first European Drug Report (EDR), the European Monitoring Centre for Drugs and Drug Addiction’s (EMCDDA) comprehensive and multi-dimensional package providing information on European drug trends and developments (European Monitoring Centre for Drug and Drug Addiction, 2013a) alongside focused analyses and country level data. This article presents highlights from the EDR package, which can be accessed in its entirety at: www.emcdda.europa.eu. Taking a broad view of the European drug landscape, the 2013 EDR reveals a number of positive developments including record levels of treatment provision accompanied by signs of erosion in injecting, new heroin use and drug-induced deaths. It also identifies a partial move away from the historical focus on small number of plant-based substances that have been transported long distances to Europe’s consumer markets. By contrast, a range of synthetic drugs and new psychoactive substances are increasingly detected, both on the illicit drug market and in the context of non-controlled substances. Cannabis continues to be Europe’s most used illicit drug and despite some evidence of decreasing trends, especially in countries with a long and established history of high prevalence, its use remains high by historical standards. An estimated 15.4 million or 11.7% of young adults (aged 15–34 years) used the drug in the previous year in Europe, including about two million daily users. Problems among older chronic users are also becoming increasingly recognized and cannabis is now the most common drug reported by clients entering specialized drug treatment for the first time. There is also increasing diversity in the types of cannabis products available, with resin and herbal cannabis, sometimes of high potency, accompanied by the recent emergence of synthetic ‘cannabis-like’ products. Cannabis use continues to be an important focus for prevention work with young people and a growing interest in the use of environmental prevention strategies, which have shown success in addressing alcohol and tobacco use, is noted. Against the backdrop of an overall increase in treatment availability for heroin users, with over 730 000 in opioid substitution treatment, indicators now suggest downwards trajectories in both use and availability of this drug. Seizures have declined in the longer term and recent market shocks or shortages have been experienced by a number of countries (Griffiths, Mounteney, & Laniel, 2012). The number of heroin users entering specialized treatment for the first time also continues to fall, less report injection of the drug, and in many countries they constitute an ageing population. A concomitant and welcome decline in new HIV diagnoses attributed to drug injection has been observed until recently, when HIV outbreaks in Greece and Romania interrupted this positive trend (European Monitoring Centre for Drug and Drug Addiction and ECDC, 2012). This serves as a timely reminder of the ongoing need to consolidate effective harm reduction and drug treatment responses in this area. The current analysis notes a high degree of interchangeability and flexibility in Europe’s stimulant market. This is evident both at the level of production, where facilities have been seized that produce both amphetamines and ecstasy depending on precursor availability, and also at the user level, where stimulant drugs, such as amphetamines, cocaine, and ecstasy are often substituted for each other, depending on availability, price and perceived ‘quality’ (European Monitoring Centre for Drug and Drug Addiction, 2013b). Cocaine remains Europe’s most commonly used stimulant with around 2.5 million or 1.9% of last year users among young adults (aged 15–34). Overall, however, both cocaine use and supply indicators have been trending downwards in the higher-prevalence countries. A recent upturn in the popularity of ecstasy has been reported in some countries, following a period when